Literature DB >> 25310104

Geographical and anatomical influences on human papillomavirus prevalence diversity in head and neck squamous cell carcinoma in Germany.

Elgar Susanne Quabius1, Jochen Haag2, André Kühnel1, Hannes Henry1, Anna Sophie Hoffmann3, Tibor Görögh1, Jürgen Hedderich4, Matthias Evert5, Achim G Beule6, Steffen Maune7, Rainald Knecht8, Attila Óvári9, Martin Durisin10, Florian Hoppe11, Silke Tribius12, Christoph Röcken2, Petra Ambrosch1, Markus Hoffmann1.   

Abstract

The increased knowledge regarding HPV-infections in head and neck squamous cell carcinoma (HNSCC) has unexpectedly contributed to several uncertainties related to i) prevalence diversities depending on tumour site and geographical origin of the patients, ii) proportion of HPV-driven tumours among HPV-DNA-positive cases, and iii) identification of patients with HPV-attributed survival benefit. To investigate this heterogeneity, we analysed 307 HNSCC cases (tonsillar, n=135; non-tonsillar, n=172) from eight health care centers mostly from Northern Germany and determined HPV-DNA/mRNA and p16INK4A-status and combined results with the patient outcome. Overall HPV-DNA prevalence rate was 23.5% (72/307); attributed to: 43.7% (59/135) and 7.6% (13/172) tonsillar and non-tonsillar cases, respectively. Among these, 96.6% tonsillar and 38.5% non-tonsillar SCC were HPV-mRNA-positive. Although the study cohort was composed of patients from regions of rather close proximity, prevalence rates showed diversities of up to 40% in HNSCC subsite analysis with the lowest prevalence for tonsillar SCC in metropolitan areas (22.2%) vs. 50.9% in rural areas. Survival analysis identified p16INK4A alone as strongest predictor, followed by HPV-DNA-status alone or in combination with p16INK4A. This survival benefit was shown for tonsillar and non-tonsillar cases. Smoking significantly correlated with HPV-status, however, it does not influence survival when stratified for HPV. In conclusion, the data emphasize the urge for further data on HPV-infection in HNSCC to, e.g. clarify to what extent survival benefits of p16INK4A-positive patients are truly attributed to HPV-infections.

Entities:  

Mesh:

Year:  2014        PMID: 25310104     DOI: 10.3892/ijo.2014.2697

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  18 in total

1.  Socioeconomic status and quality of life in patients with locally advanced head and neck cancer.

Authors:  S Tribius; M S Meyer; C Pflug; H Hanken; C-J Busch; A Krüll; C Petersen; C Bergelt
Journal:  Strahlenther Onkol       Date:  2018-05-07       Impact factor: 3.621

2.  Prevalence of HPV infection in head and neck carcinomas shows geographical variability: a comparative study from Brazil and Germany.

Authors:  Franziska Hauck; Michelle Oliveira-Silva; Johannes H Dreyer; Victor José Ferreira Perrusi; Roberto Alfonso Arcuri; Rocio Hassan; Cibele Rodrigues Bonvicino; Mario Henrique M Barros; Gerald Niedobitek
Journal:  Virchows Arch       Date:  2015-03-28       Impact factor: 4.064

Review 3.  [The innate immune system in oropharyngeal squamous cell carcinoma : Immune modulation by HPV].

Authors:  S Wagner; H Böckmann; S Gattenlöhner; J P Klussmann; C Wittekindt
Journal:  HNO       Date:  2018-04       Impact factor: 1.284

4.  SLPI and AnxA2 expression in neoplasm-free palatine tonsils is associated with smoking habit of individuals.

Authors:  Elgar S Quabius; Berit Bögershausen; Lukas Getzin; Tibor Görögh; Maximilian P Gebhard; Anna S Hoffmann; Markus Hoffmann
Journal:  Mol Clin Oncol       Date:  2017-07-24

5.  Tonsillar swabs and sputum predict SLPI- and AnxA2 expression in tonsils: A prospective study on smoking dependent SLPI- and AnxA2-expression, and tonsillar HPV infection.

Authors:  Elgar Susanne Quabius; Alessa Heinrichs; André Kühnel; Martin Laudien; Florian Hoppe; Robert Mlynski; Petra Ambrosch; Markus Hoffmann
Journal:  Oncol Lett       Date:  2022-03-28       Impact factor: 2.967

6.  Classification of TP53 mutations and HPV predict survival in advanced larynx cancer.

Authors:  Adam Scheel; Emily Bellile; Jonathan B McHugh; Heather M Walline; Mark E Prince; Susan Urba; Gregory T Wolf; Avraham Eisbruch; Francis Worden; Thomas E Carey; Carol Bradford
Journal:  Laryngoscope       Date:  2016-06-27       Impact factor: 3.325

7.  [Relevance of HPV infections in head and neck cancers : Highlights of the 2016 ASCO Annual Meeting].

Authors:  M Hoffmann
Journal:  HNO       Date:  2016-10       Impact factor: 1.284

8.  Meta-analysis of survival in patients with HNSCC discriminates risk depending on combined HPV and p16 status.

Authors:  Annekatrin Coordes; Klaus Lenz; Xu Qian; Minoo Lenarz; Andreas M Kaufmann; Andreas E Albers
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-07-31       Impact factor: 2.503

9.  [HPV infection in oral, pharyngeal and laryngeal papillomas].

Authors:  M Andratschke; H Hagedorn; A G Nerlich
Journal:  HNO       Date:  2015-11       Impact factor: 1.284

10.  Prognostic impact of additional HPV diagnostics in 102 patients with p16-stratified advanced oropharyngeal squamous cell carcinoma.

Authors:  Bernhard G Weiss; Mahalia Zoe Anczykowski; Stefan Küffer; Jennifer L Spiegel; Mattis Bertlich; Martin Canis; Friedrich Ihler; Julia Kitz; Mark Jakob
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-08-20       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.